دورية أكاديمية
A KRAS wild type mutational status confers a survival advantage in pancreatic ductal adenocarcinoma.
| العنوان: | A KRAS wild type mutational status confers a survival advantage in pancreatic ductal adenocarcinoma. |
|---|---|
| المؤلفون: | Windon AL; Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, USA., Loaiza-Bonilla A; Medical Oncology, Cancer Treatment Centers of America, Philadelphia, PA, USA., Jensen CE; Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, USA., Randall M; Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, USA., Morrissette JJD; Center for Personalized Diagnostics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Shroff SG; Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, USA. |
| المصدر: | Journal of gastrointestinal oncology [J Gastrointest Oncol] 2018 Feb; Vol. 9 (1), pp. 1-10. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: AME Publishing Group Country of Publication: China NLM ID: 101557751 Publication Model: Print Cited Medium: Print ISSN: 2078-6891 (Print) Linking ISSN: 20786891 NLM ISO Abbreviation: J Gastrointest Oncol Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Publication: Hong Kong : AME Publishing Group Original Publication: Hong Kong : Pioneer Bioscience Pub. Co. |
| مستخلص: | Background: The KRAS oncogene is a driver mutation and is present in greater than 90% of pancreatic ductal adenocarcinomas (PDAC). A subset of these tumors, however, do not harbor mutations in KRAS (wild type KRAS ). Studies have shown that patients with mutated KRAS have a poorer survival on first-line gemcitabine-based chemotherapy compared to wild type KRAS . In this study, we examined a cohort of patients with PDAC at our institution who were either wild type or mutant for the KRAS gene and assessed for differences in survival and response to different chemotherapeutic regimens. Methods: We examined clinical records of patients treated at the Abramson Cancer Center of the University of Pennsylvania from 2013 to 2017. Patients with a pancreatic mass and a histologic diagnosis of pancreatic or pancreaticobiliary adenocarcinoma were identified. Thirty-nine patients with PDAC who underwent tumor sequencing at Penn Medicine's Center for Personalized Diagnostics (CPD) were selected for further study. Twelve patients were identified whose tumors were KRAS wild type. Twenty-seven patients with PDAC whose tumors harbored KRAS mutations were selected as controls ( KRAS mutant). Results: We noted a longer overall survival (OS) among KRAS wild type patients compared to KRAS mutant patients (P=0.026). This was independent of the age at diagnosis, patient gender, stage of diagnosis, tumor morphology, mismatch repair (MMR) status, and chemotherapeutic regimen. Conclusions: Similar to previously reported studies, PDAC with a KRAS wild type mutational profile has a better prognosis with a longer OS. This improved prognosis is independent of the protocol utilized in therapy for these patients. Our findings suggest that future clinical trials in pancreatic cancer should take into consideration the presence of KRAS mutations in their pre-planned analysis when assessing the efficacy of a novel therapeutic approach. This may be a crucial factor in trial concepts and outcomes. Competing Interests: Conflicts of Interest: The authors have no conflicts of interest to declare. |
| References: | J Natl Cancer Inst. 2002 Sep 18;94(18):1358-65. (PMID: 12237281) Sci Transl Med. 2011 Jul 20;3(92 ):92ra66. (PMID: 21775669) Oncologist. 2015 Apr;20(4):e8-9. (PMID: 25777349) Ann Oncol. 1999;10 Suppl 4:82-4. (PMID: 10436792) Nat Rev Gastroenterol Hepatol. 2011 Mar;8(3):141-50. (PMID: 21383670) Cancer Res. 1994 Jun 1;54(11):3025-33. (PMID: 8187092) Clin Cancer Res. 2009 Jul 15;15(14):4674-9. (PMID: 19584151) Cancer Cell. 2012 Mar 20;21(3):418-29. (PMID: 22439937) J Clin Oncol. 2009 Jan 20;27(3):433-8. (PMID: 19064968) Cancer Res. 1996 Dec 1;56(23):5360-4. (PMID: 8968085) Am J Pathol. 1993 Aug;143(2):545-54. (PMID: 8342602) Clin Cancer Res. 2012 Aug 15;18(16):4303-12. (PMID: 22723370) Gastroenterology. 2012 Apr;142(4):730-733.e9. (PMID: 22226782) J Clin Oncol. 2009 Apr 10;27(11):1806-13. (PMID: 19273710) CA Cancer J Clin. 2013 Sep;63(5):318-48. (PMID: 23856911) Gut. 2013 Jan;62(1):112-20. (PMID: 22466618) Nat Rev Dis Primers. 2016 Apr 21;2:16022. (PMID: 27158978) Genes Dev. 2011 Apr 1;25(7):717-29. (PMID: 21406549) Science. 2009 Sep 18;325(5947):1555-9. (PMID: 19661383) Am J Pathol. 2000 May;156(5):1641-51. (PMID: 10793075) N Engl J Med. 2014 Nov 27;371(22):2140-1. (PMID: 25427123) Genes Dev. 2016 Feb 15;30(4):355-85. (PMID: 26883357) Lancet. 2011 Aug 13;378(9791):607-20. (PMID: 21620466) Cancer Genet. 2013 Dec;206(12):441-8. (PMID: 24528889) World J Gastroenterol. 2012 Oct 7;18(37):5171-80. (PMID: 23066310) Cell Rep. 2014 Dec 24;9(6):2233-49. (PMID: 25497091) Curr Opin Genet Dev. 2003 Feb;13(1):6-13. (PMID: 12573429) Am J Pathol. 1998 Jun;152(6):1501-7. (PMID: 9626054) Cell. 2012 Apr 27;149(3):656-70. (PMID: 22541435) Nature. 2013 May 30;497(7451):633-7. (PMID: 23665962) Ann Oncol. 2017 Oct 1;28(10 ):2429-2435. (PMID: 28961832) Small GTPases. 2010 Jul;1(1):2-27. (PMID: 21686117) Mol Cancer Ther. 2011 Oct;10(10):1993-9. (PMID: 21862683) Nat Rev Clin Oncol. 2009 Sep;6(9):519-27. (PMID: 19636327) Annu Rev Pathol. 2008;3:157-88. (PMID: 18039136) Cancer Biol Ther. 2009 Jan;8(2):131-5. (PMID: 19029836) Proc Natl Acad Sci U S A. 1985 Jun;82(11):3535-8. (PMID: 3858838) Nat Med. 2004 Aug;10 (8):789-99. (PMID: 15286780) Cancer Biol Ther. 2006 Aug;5(8):928-32. (PMID: 16969076) Ann Oncol. 2015 Sep;26 Suppl 5:v56-68. (PMID: 26314780) Clin Transl Gastroenterol. 2016 Mar 24;7:e157. (PMID: 27010960) |
| فهرسة مساهمة: | Keywords: Gemcitabine; KRAS; Pancreatic ductal adenocarcinoma (PDAC) |
| تواريخ الأحداث: | Date Created: 20180323 Latest Revision: 20220410 |
| رمز التحديث: | 20231215 |
| مُعرف محوري في PubMed: | PMC5848049 |
| DOI: | 10.21037/jgo.2017.10.14 |
| PMID: | 29564165 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 2078-6891 |
|---|---|
| DOI: | 10.21037/jgo.2017.10.14 |